Dirk Jan van Ginkel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dirk Jan van Ginkel has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
A. O. Kraaijeveld
Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands
1 shared publicationB. J. W. M. Rensing
Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands
1 shared publicationBas de Laat
Department of Anesthesiology, Intensive Care Medicine, Emergency Medicine and Pain Therapy, Hospital Oost-Limburg, Genk, Belgium
1 shared publicationBenno J.W. M. Rensing
Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands
1 shared publicationBenno J.W.M. Rensing
Department of Cardiology (J.B., V.J.N., D.J.v.G., M.J.S., B.J.W.M.R., L.T., J.M.t.B.), St Antonius Hospital, Nieuwegein, the Netherlands
1 shared publicationChris M. Hackeng
Department of Clinical Chemistry, St. Antonius Hospital, Nieuwegein, The Netherlands
1 shared publication
Latest Publications
- 4 December 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (4) , 1263-1278
Effects of continuation versus interruption of oral anticoagulation during transcatheter aortic valve implantation on hemostasis function
- 4 December 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (4) , 1263-1278
Effects of continuation versus interruption of oral anticoagulation during transcatheter aortic valve implantation on hemostasis function
- Open Access
- 1 November 2021
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 29 (12) , 632-642
Major threats to early safety after transcatheter aortic valve implantation in a contemporary cohort of real-world patients
Introduction: Despite considerable advances in the last decade, major adverse events remain a concern after transcatheter aortic valve implantation (TAVI). The aim of this study was to provide a detailed overview of their underlying causes and contributing factors in order to identify key domains for quality improvement. Methods: This observational, prospective registry included all patients undergoing TAVI between 31 December 2015 and 1 January 2020 at the St. Antonius Hospital in Nieuwegein and the University Medical Centre in Utrecht. Outcomes of interest were all-cause mortality, stroke, major bleeding, life-threatening or disabling bleeding, major vascular complications, myocardial infarction, severe acute kidney injury and conduction disturbances requiring permanent pacemaker implantation within 30 days after TAVI, according to the Valve Academic Research Consortium‑2 criteria. Results: Of the 1250 patients who underwent TAVI in the evaluated period, 146 (11.7%) developed a major complication. In 54 (4.3%) patients a thromboembolic event occurred, leading to stroke in 36 (2.9%), myocardial infarction in 13 (1.0%) and lower limb ischaemia in 11 (0.9%). Major bleeding occurred in 65 (5.2%) patients, most frequently consisting of acute cardiac tamponade (n = 25; 2.0%) and major access-site bleeding (n = 21; 1.7%). Most complications occurred within 1 day of the procedure. Within 30 days a total of 54 (4.3%) patients died, the cause being directly TAVI-related in 30 (2.4%). Of the patients who died from causes that were not directly TAVI-related, 14 (1.1%) had multiple hospital-acquired complications. Conclusion: A variety of underlying mechanisms and causes form a wide spectrum of major threats affecting early safety in 11.7% of patients undergoing TAVI in a contemporary cohort of real-world patients.
- 1 November 2021
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 29 (12) , 632-642
Open AccessMajor threats to early safety after transcatheter aortic valve implantation in a contemporary cohort of real-world patients
Introduction: Despite considerable advances in the last decade, major adverse events remain a concern after transcatheter aortic valve implantation (TAVI). The aim of this study was to provide a detailed overview of their underlying causes and contributing factors in order to identify key domains for quality improvement. Methods: This observational, prospective registry included all patients undergoing TAVI between 31 December 2015 and 1 January 2020 at the St. Antonius Hospital in Nieuwegein and the University Medical Centre in Utrecht. Outcomes of interest were all-cause mortality, stroke, major bleeding, life-threatening or disabling bleeding, major vascular complications, myocardial infarction, severe acute kidney injury and conduction disturbances requiring permanent pacemaker implantation within 30 days after TAVI, according to the Valve Academic Research Consortium‑2 criteria. Results: Of the 1250 patients who underwent TAVI in the evaluated period, 146 (11.7%) developed a major complication. In 54 (4.3%) patients a thromboembolic event occurred, leading to stroke in 36 (2.9%), myocardial infarction in 13 (1.0%) and lower limb ischaemia in 11 (0.9%). Major bleeding occurred in 65 (5.2%) patients, most frequently consisting of acute cardiac tamponade (n = 25; 2.0%) and major access-site bleeding (n = 21; 1.7%). Most complications occurred within 1 day of the procedure. Within 30 days a total of 54 (4.3%) patients died, the cause being directly TAVI-related in 30 (2.4%). Of the patients who died from causes that were not directly TAVI-related, 14 (1.1%) had multiple hospital-acquired complications. Conclusion: A variety of underlying mechanisms and causes form a wide spectrum of major threats affecting early safety in 11.7% of patients undergoing TAVI in a contemporary cohort of real-world patients.